- Paolo Bruzzi, National Cancer Research Institute
- Carlos Caldas, Cambridge Research Institute
- Ian Cree, Warwick Medical School, Coventry
- Shoukat Dedhar, British Columbia Cancer Agency
- John A Hartley, University College London
- Manami Inoue, University of Tokyo
- Ferdinando Mannello, University Carlo Bo
- Mark McKeage, University of Auckland
- Christophe Nicot, Kansas University Medical Center
- Stephen P Povoski, The Ohio State University
- Charles Rosser, University of Hawaii Cancer Center
- Dirk Vordermark, Martin Luther University Halle-Wittenberg
- Dafne Solera, BioMed Central
A meta-analysis of published studies confirms that higher intake ratio of n-3/n-6 polyunsaturated fatty acids (PUFAs), found in oily fish, vegetable oils and seeds, is associated with lower risk of breast cancer.
A double blind crossover randomized clinical trial shows that Calcium and Magnesium (Ca/Mg) infusion in colorectal cancer patients does not alter the clinical pharmacokinetics of oxaliplatin, but it also fails to reduce acute its neurotoxicity.
The PKCδ activator compound AD198 displays anti-tumour effect on malignant B cells via a mechanism that is independent of PKCδ nuclear translocation but involves inactivation of the tumor suppressor TRAF3 and c-Myc up-regulation.
Silica microparticles loaded with doxorubicin (DOX) and modified with a mesothelin specific antibody demonstrate higher effectiveness and lower toxicity than DOX systemic treatment in a mouse xenograft model of human peritoneal mesothelioma.
BMC Cancer 2014, 14:90
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.
Join the Editorial Board!
Are you interested in becoming an Editorial Board member for BMC Cancer and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor, please simply contact us at email@example.com, enclosing a summary of your research interests and relevant expertise. We look forward to hearing from you.
Christudas Morais, David W Johnson, David A Vesey, and Glenda C Gobe1BMC Cancer 2013, 13:14 (10 January 2013)
Section Editor's profile
Mark McKeage is a medical oncologist and associate professor in the department of pharmacology and clinical pharmacology and co-director of the Auckland Cancer Society Research Centre at the university of Auckland, New Zealand. His current research focuses on how membrane transporters determine response and handling of platinum-based anticancer drugs. In addition, he leads a programme of phase I oncology trials at his centre.
"BMC Cancer is the leading Open Access international journal in the field of oncology. By publishing over 500 articles per year, BMC Cancer offers rapid dissemination of the most recent information of interest to the broad oncology science community."
Prof McKeage is the Section Editor of the Clinical oncology- medical oncology and pharmacology section of BMC Cancer.
BMC series blog
- 04 March 2014
- Highlights of the BMC-series: February 2014
- 03 March 2014
- Hiding the truth – how one bird fools another
- 27 February 2014
- BMC Medical Imaging at the European Congress of Radiology 2014